Navigation Links
Gladstone scientist Deepak Srivastava named fellow of the AAAS
Date:12/16/2011

SAN FRANCISCO, CADecember 16, 2011The American Association for the Advancement of Science (AAAS) has named Gladstone Senior Investigator Deepak Srivastava, MD, a Fellow for his efforts to advance science and its applications.

Dr. Srivastava directs cardiac and stem cell research at Gladstone, an independent and nonprofit biomedical-research organization whose primary research efforts are focused in the areas of cardiovascular disease, virology and neurological disease. AAAS, which will honor all newly elected Fellows on February 18 during the 2012 AAAS Annual Meeting in Vancouver, B.C., Canada, elected Dr. Srivastava in recognition of his distinguished contributions and advancements in the fields of congenital heart disease, cardiac development and stem cell biology.

"I am honored by this recognition from my peers, and humbled to be among such an esteemed group of scientists," said Dr. Srivastava, who is also a professor of pediatrics, biochemistry and biophysics at the University of California, San Francisco (UCSF), with which Gladstone is affiliated.

Dr. Srivastava joins five other Gladstone scientists who are already AAAS Fellows: President R. Sanders Williams, MD; President Emeritus and Senior Investigator Robert Mahley, MD, PhD; Senior Investigator Warner Greene, MD, PhD, who directs Gladstone's virology and immunology research; and Senior Investigator Eric Verdin, MD, who is the associate director for virology and immunology research.

Dr. Srivastava's studies focus on applying modern genetic and stem cell technologies to identify the causes of human heart disease. His laboratory studies the molecular events regulating early and late developmental decisions that instruct progenitor cells to become cardiac cellsand subsequently fashion a functioning heart.

Drawing on his expertise in developmental biology, Dr. Srivastava and his lab have reprogrammed connective tissue in the heart directly into beating heart cellsa process that may help regenerate damaged heart muscle. Understanding the causes of heart disease and applying knowledge of these cardiac development pathways may be useful in preventing congenital defects and devising new therapies to treat acquired heart disease, particularly with cardiac-specific differentiation of embryonic stem cells. Congenital heart disease affects nearly 1 out of every 100 babies born worldwide and is the most common cause of death from a birth defect.

"We are delighted and gratified that the AAAS has recognized Deepak's achievements in the field of cardiovascular research," said Dr. Williams. "We are optimistic that his research will contribute to finding solutions to help the millions who suffer from heart disease."

Before joining Gladstone in 2005, Dr. Srivastava was a professor in the department of pediatrics and molecular biology at the University of Texas Southwestern (UTSW) Medical Center in Dallas. He has received numerous honors and awards, including endowed chairs at UTSW and UCSF, as well as election to the American Society for Clinical Investigation, the Society for Pediatric Research, and the American Academy of Arts and Sciences.


'/>"/>

Contact: Anne Holden
anne.holden@gladstone.ucsf.edu
415-734-2534
Gladstone Institutes
Source:Eurekalert

Related biology news :

1. Gladstone scientist receives American Heart Associations Katz prize for cardiovascular research
2. Gladstone founder receives American Heart Association Distinguished Scientist Award
3. Gladstone scientists identify protein form linked to Huntingtons disease
4. Gladstone scientist finds new target for treating symptoms of Parkinsons disease
5. Gladstone scientists offer new insight into the regulation of stem cells and cancer cells
6. Gladstone to receive $5.6 million in federal funds to seek a cure for AIDS
7. Gladstone scientists identify genes involved in embryonic heart development
8. Gladstone scientists uncover mechanism for the major genetic risk factor of Alzheimers disease
9. Gladstone scientists link hepatitis C virus infection to fat enzyme in liver cells
10. Gladstones Shinya Yamanaka wins Kyoto prize
11. Gladstone and Institute for Systems Biology collaborate on Huntingtons disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2016)... -- The American College of Medical Genetics and Genomics was once ... one of the fastest-growing trade shows during the Fastest 50 ... Las Vegas . Winners ... each of the following categories: net square feet of paid ... The 2015 ACMG Annual Meeting was ranked 23 out of ...
(Date:6/22/2016)... On Monday, the Department of Homeland Security ... solutions for the Biometric Exit Program. The Request for ... (CBP), explains that CBP intends to add biometrics to ... United States , in order to deter visa ... Logo - http://photos.prnewswire.com/prnh/20160622/382209LOGO ...
(Date:6/20/2016)... , June 20, 2016 Securus Technologies, ... technology solutions for public safety, investigation, corrections and ... prisons involved, it has secured the final acceptance ... facilities for Managed Access Systems (MAS) installed. Furthermore, ... facilities to be installed by October, 2016. MAS ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or "the ... major shareholders, Clean Technology Fund I, LP and Clean ... based venture capital funds which together hold approximately ... fully diluted, as converted basis), that they have entered ... equity holdings in Biorem to TUS Holdings Co. Ltd. ...
(Date:6/27/2016)... ... 27, 2016 , ... Rolf K. Hoffmann, former senior vice ... University of North Carolina Kenan-Flagler Business School effective June 27. , ... with a focus on the school’s international efforts, leading classes and participating in ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... While the ... such as the Cary 5000 and the 6000i models are higher end machines that ... the height of the spectrophotometer’s light beam from the bottom of the cuvette holder. ...
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
Breaking Biology Technology: